Skip to main content

Table 2 Changes from baseline in inflammatory indices, dose of corticosteroids, and visual acuity

From: Ocular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis: primary 6-month results of the SAVE Study

 

All (n= 28)

Group 1 (n= 14)

Group 2 (n= 14)

Baseline

Month 3

Month 6

Baseline

Month 3

Month 6

Baseline

Month 3

Month 6

Anterior chamber cells (number of patients)

         

 None

24

26

27

11

13

14

13

13

13

 0.5+

3

2

1

2

1

-

1

1

1

 1+

1

-

-

1

-

-

-

-

-

 2+

-

-

-

-

-

-

-

-

-

 3+

-

-

-

-

-

-

-

-

-

 4+

-

-

-

-

-

-

-

-

-

Vitreous cells (number of patients)

         

 None

14

22

27

8

11

11

6

11

11

 0.5+

5

5

1

3

3

2

2

2

1

 1+

7

1

-

3

-

1

4

1

2

 2+

2

-

-

-

-

-

2

-

-

 3+

-

-

-

-

-

-

-

-

-

 4+

-

-

-

-

-

-

-

-

-

Vitreous haze (number of patients)

         

 None

-

13

7

-

6

3

-

7

4

 0.5+

8

11

16

3

6

9

5

5

7

 1+

11

4

5

7

2

2

4

2

3

 2+

8

-

-

3

-

-

5

-

-

 3+

1

-

-

1

-

-

-

-

-

 4+

-

-

-

-

-

-

-

-

-

Corticosteroids dose (median mg/day ± SD)

         

 Category 1 (n = 7)

NA

NA

NA

NA

NA

NA

NA

NA

NA

 Category 2 (n = 13)

20 ± 15.7

12.5 ± 6.8

8 ± 5.7

25 ± 18.1

13.8 ± 8

7.8 ± 7.1

20 ± 11.4

12.5 ± 4.5

8.0 ± 1.9

 Category 3 (n = 7)

9 ± 3.1

4 ± 2.9

3 ± 2.2

8.0 ± 2.1

4.0 ± 2.5

3.0 ± 1.8

9.0 ± 4.0

5.5 ± 3.5

3.0 ± 2.6

Visual acuity (mean ±SD)

         

 Category 1

62 ± 13.3

66 ± 13.1

61 ± 14.5

55 ± 6.2

59 ± 12.7

51 ± 10.6

68 ± 15.4

72 ± 11.5

69 ± 12.8

 Category 2

71 ± 16.8

72 ± 16.3

72 ± 18.1

69 ± 15.3

70 ± 14.4

69 ± 16.9

73 ± 20.6

77 ± 20.1

76 ± 21.3

 Category 3

72 ± 22.6

74 ± 18.3

74 ± 15.8

66 ± 23.1

71 ± 16.3

69 ± 14

75 ± 24.2

77 ± 21

76 ± 17.8

  1. n, number; SD, standard deviation; NA, not applicable.